Therefore, the results from this ROP Study of patients with long-term H therapy are of significant interest to the medical oncology community, as many physicians have ongoing queries about long-term management of patients with HER2-positive locally advanced/metastatic breast cancer or HER2-positive locally advanced/metastatic gastric/GEJ cancer who are being treated with H. To our knowledge, this is the longest study of patients receiving long-term H therapy for HER2-positive breast cancer or for HER2-positive gastric/GEJ cancer. The gene discussed is ERBB2; the disease is breast carcinoma.